Literature DB >> 30367191

[What is established in cell therapies? : Possibilities and limits in immuno-oncology].

A Quaiser1, U Köhl2,3,4.   

Abstract

Cell and gene therapy as part of immuno-oncology has reached an important milestone in medicine. After decades of experience stem cell transplantation is well established with worldwide >1 million transplantations to date. Due to the improved success of the last years using chimeric antigen receptor (CAR) T cells for CD19 positive leukemia and lymphomas, the interest in cellular therapies is continuously increasing. The current review also gives a short overview about donor lymphocytes, antigen-specific T cells, regulatory T cells, natural killer (NK) cells, mesenchymal stromal cells and induced pluripotent stem (iPS) cells in immuno-oncology.

Entities:  

Keywords:  Advanced therapy medicinal products; CAR-T-Cells; Gene therapy; Immunotherapy; Stem cell transplantation

Mesh:

Year:  2018        PMID: 30367191     DOI: 10.1007/s00108-018-0516-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

1.  CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications.

Authors:  Ulrike Köhl; Stanislava Arsenieva; Astrid Holzinger; Hinrich Abken
Journal:  Hum Gene Ther       Date:  2018-04-05       Impact factor: 5.695

2.  Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT.

Authors:  Judith Feucht; Kathrin Opherk; Peter Lang; Simone Kayser; Lena Hartl; Wolfgang Bethge; Susanne Matthes-Martin; Peter Bader; Michael H Albert; Britta Maecker-Kolhoff; Johann Greil; Hermann Einsele; Paul-Gerhardt Schlegel; Friedhelm R Schuster; Bernhard Kremens; Claudia Rossig; Bernd Gruhn; Rupert Handgretinger; Tobias Feuchtinger
Journal:  Blood       Date:  2015-01-23       Impact factor: 22.113

Review 3.  Donor leukocyte transfusions for leukemic relapse.

Authors:  F van Rhee; H J Kolb
Journal:  Curr Opin Hematol       Date:  1995-11       Impact factor: 3.284

Review 4.  TRUCKs: the fourth generation of CARs.

Authors:  Markus Chmielewski; Hinrich Abken
Journal:  Expert Opin Biol Ther       Date:  2015-05-18       Impact factor: 4.388

Review 5.  Haploidentical transplantation for acute lymphoblastic leukemia in childhood.

Authors:  Thomas Klingebiel; Rupert Handgretinger; Peter Lang; Peter Bader; Dietrich Niethammer
Journal:  Blood Rev       Date:  2004-09       Impact factor: 8.250

Review 6.  Natural killer cell-mediated immunosurveillance of human cancer.

Authors:  Karl-Johan Malmberg; Mattias Carlsten; Andreas Björklund; Ebba Sohlberg; Yenan T Bryceson; Hans-Gustaf Ljunggren
Journal:  Semin Immunol       Date:  2017-09-06       Impact factor: 11.130

7.  Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.

Authors:  Wolfgang A Bethge; Christoph Faul; Martin Bornhäuser; Gernot Stuhler; Dietrich W Beelen; Peter Lang; Matthias Stelljes; Wichard Vogel; Matthias Hägele; Rupert Handgretinger; Lothar Kanz
Journal:  Blood Cells Mol Dis       Date:  2007-09-14       Impact factor: 3.039

8.  Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.

Authors:  Waseem Qasim; Hong Zhan; Sujith Samarasinghe; Stuart Adams; Persis Amrolia; Sian Stafford; Katie Butler; Christine Rivat; Gary Wright; Kathy Somana; Sara Ghorashian; Danielle Pinner; Gul Ahsan; Kimberly Gilmour; Giovanna Lucchini; Sarah Inglott; William Mifsud; Robert Chiesa; Karl S Peggs; Lucas Chan; Farzin Farzeneh; Adrian J Thrasher; Ajay Vora; Martin Pule; Paul Veys
Journal:  Sci Transl Med       Date:  2017-01-25       Impact factor: 17.956

Review 9.  Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Front Immunol       Date:  2018-02-15       Impact factor: 7.561

10.  Advances in clinical NK cell studies: Donor selection, manufacturing and quality control.

Authors:  U Koehl; C Kalberer; J Spanholtz; D A Lee; J S Miller; S Cooley; M Lowdell; L Uharek; H Klingemann; A Curti; W Leung; E Alici
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

View more
  1 in total

1.  Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.

Authors:  Agnes Bonifacius; Sabine Tischer-Zimmermann; Maria Michela Santamorena; Philip Mausberg; Josephine Schenk; Stephanie Koch; Johanna Barnstorf-Brandes; Nina Gödecke; Jörg Martens; Lilia Goudeva; Murielle Verboom; Jana Wittig; Britta Maecker-Kolhoff; Herrad Baurmann; Caren Clark; Olaf Brauns; Martina Simon; Peter Lang; Oliver A Cornely; Michael Hallek; Rainer Blasczyk; Dominic Seiferling; Philipp Köhler; Britta Eiz-Vesper
Journal:  Front Bioeng Biotechnol       Date:  2022-04-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.